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Abstract
Breast cancer can be caused by germline mutations in several genes that are responsible for different hereditary cancer
syndromes. Some of the genes causing the Fanconi anemia (FA) syndrome, such as BRCA2, BRIP1, PALB2, and RAD51C, are
associated with high or moderate risk of developing breast cancer. Very recently, SLX4 has been established as a new FA
gene raising the question of its implication in breast cancer risk. This study aimed at answering this question sequencing the
entire coding region of SLX4 in 526 familial breast cancer cases from Italy. We found 81 different germline variants and none
of these were clearly pathogenic. The statistical power of our sample size allows concluding that in Italy the frequency of
carriers of truncating mutations of SLX4 may not exceed 0.6%. Our results indicate that testing for SLX4 germline mutations
is unlikely to be relevant for the identification of individuals at risk of breast cancer, at least in the Italian population.
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Introduction
Breast cancer is a heterogeneous disease that can be caused by
genetic and non-genetic factors. Genetic susceptibility to breast
cancer is due to a large spectrum of germline variants. A consistent
fraction of familial cases is due to rare high-penetrance mutations
in the BRCA1 and BRCA2 genes. Other high or moderate
penetrance alleles have been identified in genes responsible for
hereditary syndromes of which cancer predisposition is one of the
features. Namely, these are TP53 causing the Li-Fraumeni
syndrome, PTEN causing the Cowden syndrome, STK11 causing
the Peutz-Jeghers syndrome, CDH1 causing diffuse gastric cancer
and ATM causing ataxia telangiectasia [1], [2]. Fanconi anemia
(FA) is another cancer susceptibility syndrome characterized by
genome instability, congenital abnormalities and bone marrow
failure. This recessive syndrome is genetically heterogeneous
arising from mutations in one of at least 13 different FA genes
(FANCA-C, D1, D2, E-G, I, J and L-N). In 2002, the discovery
that BRCA2 and FANCD1 are the same gene, provided the first
evidence of common genetic bases for breast cancer susceptibility
and FA [3]. Subsequent studies reinforced this connection showing
that truncating mono-allelic mutations in BRIP1/FANCJ and
PALB2/FANCN had a frequency of approximately 1% in familial
breast cancer cases [4], [5]. Moreover, the newly ascertained FA
gene RAD51C harbored a truncating mutation in 4/1,100 (0.5%)
of familial breast cancer cases from Germany [6]. Very recently,
bi-allelic truncating mutations of SLX4 were found in FA patients
unlinked to previously identified FA genes [7], [8]. So far, while
BRCA2, BRIP1, PALB2, and RAD51C are associated with high or
moderate breast cancer risk, the impact of SLX4 on breast cancer
remains to be measured. In this context, we sequenced the entire
coding region and the intron-exon boundaries of SLX4 in 526
familial breast cancer cases from Italy.
Methods
Patients
The 526 female index cases included in this study were
ascertained at the Medical Genetics Units of the Fondazione
IRCCS Istituto Nazionale Tumori and the Istituto Europeo di
Oncologia in Milan, from March 2003 to August 2008. All
subjects, therein referred to as BRCAX cases, were probands of
families fulfilling previously reported diagnostic criteria for
hereditary breast/ovarian cancer, based on disease family history
and age at disease onset [9], [10]. All index cases were verified not
to carry deleterious mutations or unclassified variants in BRCA1 or
BRCA2 genes, following direct sequencing or denaturing high-
performance liquid chromatography (DHPLC) analysis of all
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All participants in this study signed an informed consent to the use
of their biological samples for research purposes. This study was
approved by the Ethic Committee of Fondazione IRCCS Istituto
Nazionale Tumori, Milan.
Mutation screening
The mutation analysis was performed by single strand DNA
sequencing using primers previously described [7], with the
exception of primers for exons 5, 8, 12B-F, 13 and 15 that were
re-designed. Sequences of these primers are available upon
request.
All newly identified variants have been deposited in the
Database of Short Genetic Variations (dbSNP; http://www.ncbi.
nlm.nih.gov/projects/SNP/).
Results and Discussion
In the 526 BRCAX cases, we identified several variants, but no
one could be considered as a clear pathogenic mutation. A total of
81 different variants were found and none was truncating (Table
S1). Of these variants, 35 were previously annotated in public
databases including dbSNP [11], 1000 Genomes [12], and Exome
Variant Server (http://evs.gs.washington.edu/EVS/) and report-
ed with carrier frequency $1% in Caucasians and thus considered
as likely neutral polymorphisms (Table S1). Of the 46 remaining
variants, 29 were missense, 14 were silent, two were intronic and
one was a 3-nucleotide in-frame deletion causing the loss of a
single conserved amino-acid (p.Ile1195del). All 46 variants were
analyzed in silico to study their potential impact on mRNA splicing
using the following four programs: Berkeley Drosophila Genome
Project [13], NetGene2 [14], [15], SplicePredictor [16], and
GeneSplicer [17], For all but two variants the majority of
programs predicted no effect on splicing. The two variants were
the c.833G.A, predicted by three programs to create a new
donor splice site, and the c.5155T.A, predicted by two programs
to abolish the physiological acceptor site of exon 15. These
predictions were confirmed using an additional program (Max-
EntScan) [18]. The 29 missense variants were studied in silico by
PolyPhen-2 [19], SIFT [20] and SNP&GO [21] programs and
only the p.Ser1719Tyr was classified as a variant with possibly
pathogenic effect by all three programs.
Pathogenic mutations of the FA genes BRIP1, PALB2, and
RAD51C have been identified in familial cases from different
populations with frequencies of 1% to 2% [1], [6], [22]. The vast
majority of them are truncating. In Italian breast cancer families,
only PALB2 has been studied and truncating mutations were
reported with frequencies ranging between 0.8 and 2.1%[23],
[24], [25]. Therefore, the failure of identifying this type of
mutations in SLX4 in a large set of BRCAX cases argues against its
role as a breast cancer predisposing gene. In addition, if present,
these mutations must be very rare in the Italian population. For
our sample size of 526 in which no events (no carriers of truncating
SLX4 mutations) have been observed, the upper limit of the 95%
confidence interval of the event probability is 0.006. This indicates
that a population frequency of truncating mutations greater than
0.6% would result in a probability of less than 5% of not finding at
least one carrier in our sample set and, accordingly, that in the
Italian population the frequency of carriers of truncating
mutations of SLX4 may not exceed 0.6%.
We cannot exclude that some of the 81 non-truncating variants
we found may be pathogenic or associated with increased risk of
breast cancer. In particular, the c.833G.A, c.3583_3585delATT
and the c.5155T.A variants were considered to have the higher
theoretical probability of being pathogenic, based on in silico
analyses or phylogenetic conservation. Additional studies, includ-
ing in vitro transcript analyses and functional assays would be
required to verify the impact of these mutations on gene
functioning. In addition, these variants were very rarely observed
in cases (,0,2%) and the assessment of their pathogenicity by case-
control studies was not carried out, since it would have required a
very large sample size. Segregation analysis was prevented by lack
of additional family members. Finally, as another limit of this
study, we cannot rule out SLX4 mutations not detectable by
sequence analyses, including copy number alterations and gene
rearrangements, could be present in our sample set.
Our data are in line with those from a small study in 52 German
and Byelorussian hereditary breast cancer cases, where extensive
genetic variation was shown with lack of any clear pathogenic
mutation [26], providing evidence against impact of SLX4 on
breast cancer risk in the tested populations. However, SLX4 might
impact on breast cancer risk in populations such as Indians,
Americans, and Northern Europeans, where the FA families with
SLX4 truncating mutations originated from [7], [8].
In conclusion, no clear pathogenic mutations were found in 526
Italian BRCAX cases, supporting the hypothesis that SLX4 is
unlikely to be a breast cancer gene. Moreover, our data indicated
that truncating mutations of SLX4 are extremely rare, if not
absent, in Italy. Consequently, although our approach might have
missed pathogenic SLX4 alterations, we argue that at present
testing for germline mutations in this gene is unlikely to be relevant
for the identification of individuals at risk of breast cancer, at least
in the Italian population.
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